Data gathered: November 27
Alternative Data for ESSA Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,007 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About ESSA Pharma
ESSA Pharma Inc., a clinical-stage pharmaceutical company, is focused on developing novel and proprietary therapies for the treatment of prostate cancer. The company is headquartered in Vancouver, Canada.
| Price | $1.79 |
| Target Price | Sign up |
| Volume | 150,790 |
| Market Cap | $80M |
| Year Range | $1.4 - $9.19 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIXNovember 25 - Finnhub |
|
 |
ESSA Pharma And 2 Other US Penny Stocks To WatchNovember 10 - Yahoo |
 |
Insider Selling: ESSA Pharma Inc. (NASDAQ:EPIX) Major Shareholder Sells 7,879,583 Shares of StockNovember 8 - ETF Daily News |
 |
Piper Sandler Downgrades ESSA Pharma (NASDAQ:EPIX) to NeutralNovember 7 - ETF Daily News |
|
ESSA Pharma (NASDAQ:EPIX) Rating Lowered to Market Perform at OppenheimerNovember 6 - ETF Daily News |
|
**ESSA Pharma Terminates Phase 2 Study on Prostate Cancer Treatment Masofaniten**November 5 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 0 | 3.2M | -3.2M | -7.2M | -7.2M | -0.160 |
| Q1 '24 | 14,000 | 4.3M | -4.3M | -9M | -9M | -0.200 |
| Q4 '23 | 0 | 2.2M | -2.2M | -6M | -5.9M | -0.140 |
| Q3 '23 | 0 | 1.9M | -1.9M | -5.5M | -5.5M | -0.120 |
| Q2 '23 | 0 | 2.6M | -2.6M | -7.3M | -7.3M | -0.170 |
Insider Transactions View All
| BB BIOTECH AG filed to sell 1,879,583 shares at $1.5. November 5 '24 |
| Virsik Peter filed to sell 7,776 shares at $6. October 7 '24 |
| Virsik Peter filed to sell 8,470 shares at $6. September 9 '24 |
| Virsik Peter filed to sell 9,164 shares at $6. September 3 '24 |
Similar companies
Read more about ESSA Pharma (EPIX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of ESSA Pharma?
The Market Cap of ESSA Pharma is $80M.
What is the current stock price of ESSA Pharma?
Currently, the price of one share of ESSA Pharma stock is $1.79.
How can I analyze the EPIX stock price chart for investment decisions?
The EPIX stock price chart above provides a comprehensive visual representation of ESSA Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ESSA Pharma shares. Our platform offers an up-to-date EPIX stock price chart, along with technical data analysis and alternative data insights.
Does EPIX offer dividends to its shareholders?
As of our latest update, ESSA Pharma (EPIX) does not offer dividends to its shareholders. Investors interested in ESSA Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ESSA Pharma?
Some of the similar stocks of ESSA Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.